ConductScience.org, home

Library / Trial comparisons

AMR101 vs Placebo: Composite of CV Death, Nonfatal MI (Including Silent MI), Nonfatal Stroke, Coronary Revascularization, or Unstable Angina Determined to be Caused by Myocardial Ischemia by Invasive / Non-invasive Testing and Requiring Emergent Hospitalization.

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNoteSource
Risk in group 10.1720.1610.184wilsonClinicalTrials.gov
Risk in group 20.220.2080.233wilsonClinicalTrials.gov
Risk difference, group 1 minus group 2-0.0479-0.0651-0.0307newcombe hybrid scoreClinicalTrials.gov
Risk ratio, group 1 over group 20.7830.7160.855logClinicalTrials.gov
Odds ratio, group 1 over group 20.7370.6610.823logClinicalTrials.gov
Number needed to treat, for one fewer participant with the outcome on AMR101 than on Placebo20.915.432.6from the risk difference intervalClinicalTrials.gov

Groups 2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov codeSource
Group 1AMR101AMR101: Parallel Assignment7054,089OG000ClinicalTrials.gov
Group 2PlaceboPlacebo: Parallel Assignment9014,090OG001ClinicalTrials.gov

Outcome 5

FieldValueSource
TypePRIMARYClinicalTrials.gov
Title
Composite of CV Death, Nonfatal MI (Including Silent MI), Nonfatal Stroke, Coronary Revascularization, or Unstable Angina Determined to be Caused by Myocardial Ischemia by Invasive / Non-invasive Testing and Requiring Emergent Hospitalization.
ClinicalTrials.gov
Description
The primary outcome measure was the number of patients with a first occurrence of any component of the composite of CV death, nonfatal MI (including silent MI), nonfatal stroke, coronary revascularization, or unstable angina determined to be caused by myocardial ischemia by invasive / non-invasive testing and requiring emergent hospitalization during the follow-up period.
ClinicalTrials.gov
Time frameTotal follow-up time of up to approximately 6 years.ClinicalTrials.gov
PopulationClinicalTrials.gov

Trial 8

FieldValueSource
TitleA Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on StatinClinicalTrials.gov
NCT numberNCT01492361ClinicalTrials.gov
PhasesPHASE3ClinicalTrials.gov
ConditionsCardiovascular DiseasesClinicalTrials.gov
InterventionsAMR101, Placebo, Statin therapyClinicalTrials.gov
Lead sponsorAmarin Pharma Inc.ClinicalTrials.gov
Results first posted2022-04-14ClinicalTrials.gov
Results on ClinicalTrials.govhttps://clinicaltrials.gov/study/NCT01492361?tab=resultsClinicalTrials.gov

Source 4

FieldValueSource
Releasetrial-comparisons-2026-03-23-0.1.0ClinicalTrials.gov
Release manifest SHA-256f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57ClinicalTrials.gov
AACT copy2026-03-23ClinicalTrials.gov
Tables readoutcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquetClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.